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Dissecting the genomic activity of 
a transcriptional regulator by the 
integrative analysis of omics data
Giulio Ferrero  1,2,3, Valentina Miano  1,3, Marco Beccuti2, Gianfranco Balbo1,2, Michele De 
Bortoli1,3 & Francesca Cordero1,2
In the study of genomic regulation, strategies to integrate the data produced by Next Generation 
Sequencing (NGS)-based technologies in a meaningful ensemble are eagerly awaited and must 
continuously evolve. Here, we describe an integrative strategy for the analysis of data generated 
by chromatin immunoprecipitation followed by NGS which combines algorithms for data overlap, 
normalization and epigenetic state analysis. The performance of our strategy is illustrated by presenting 
the analysis of data relative to the transcriptional regulator Estrogen Receptor alpha (ERα) in MCF-7 
breast cancer cells and of Glucocorticoid Receptor (GR) in A549 lung cancer cells. We went through the 
definition of reference cistromes for different experimental contexts, the integration of data relative 
to co-regulators and the overlay of chromatin states as defined by epigenetic marks in MCF-7 cells. 
With our strategy, we identified novel features of estrogen-independent ERα activity, including FoxM1 
interaction, eRNAs transcription and a peculiar ontology of connected genes.
DNA regulatory regions represent an important part of the genome, where DNA binding Transcription Factors 
(TF) and a large number of co-regulators cooperate to convey cellular information and control gene activity. 
Recent genome-wide analyses, conducted by ENCODE and other projects in a variety of cell lines and tissues, led 
to the unexpected observation that distant or proximal non-promotorial regulatory regions, defined as enhanc-
ers, outnumber gene promoters by a factor of ten1. They appear to serve in a developmentally-regulated fashion, 
and only a fraction of them is poised or active in a defined cell type at any specific time. Enhancer activity status 
is quite precisely defined by histone Post Translational Modifications (PTMs), TF and coregulator binding, and 
enhancer RNAs (eRNAs) transcription2. The genomic activity of a TF or a coregulatory factor (namely collectively 
TR for Transcriptional Regulators) is studied using Chromatin immunoprecipitation (ChIP) in combination with 
Next Generation Sequencing (NGS). Binding sites are often taken as a proxy for the regulatory effects of TRs. 
However, not all binding events are functionally important3. First, the DNA-bound TR may lack a key cofactor 
or PTMs. Second, it has been shown that only more stable binding events are productive, as opposed to erratic, 
short-lived events that nonetheless are picked up by ChIP analysis4. Identifying true functional TR Binding Sites 
(TRBSs) has great relevance not only in regulatory genomics, but also in medical genetics and pathology5. This 
task can be afforded by leveraging the increasingly wide data available in public repositories concerning, in addi-
tion to TR binding, data on chromatin accessibility, histone PTMs, CpG methylation, as well as expression data 
by microarray and RNA-Seq technologies6. This data can be mined allowing construction of robust cistromes 
annotated with their activity status, finally obtaining classification of TRBS subsets with coherent functions.
Despite simple rationale, data integration is not trivial due to wide heterogeneity of the data available. The first 
reason is technical, since data derive from several variants of the ChIP assay or chromatin accessibility assays, or 
other, run on different NGS platforms at different sequencing coverages, often resulting in quite diverging num-
bers of binding sites. Second, data have different formats, either as raw sequencing reads or processed data includ-
ing genomic coordinates (ChIP peak sets), genomic coverage (genomic signal profiles), or reads alignment files.
Thus, when integrating heterogeneous data from different studies, a robust approach is mandatory. Two major 
issues should be dealt with: first, how binding regions are defined; second, since measurements with ChIP are 
inherently not quantitative, data normalization is required. Bioinformatics tools to afford these issues exist7–12 
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but, while these tools can be successfully used for comparative analysis of ChIP data, a “start-to-end” strategy 
to dissect progressively a TR genomic activity by means of genomic and epigenomic data integration still awaits 
implementation.
A quite impressive number of studies from several labs comprising ours have reported Estrogen Receptor α 
(ERα, ESR1) genomic binding, ERα-controlled transcriptomes and biological effects of agonists and antagonists 
in human breast cancer cells13, 14. Surprisingly though, there is no systematic analysis leading to definition of a 
reference cistrome and to identification of the differential activity of ERα in different experimental contexts and 
with different ligands or, notably, in absence of estrogen as we reported previously15 and that represents possibly 
one of the most puzzling activity of this TR.
We describe here a “start-to-end” strategy to define a consensus cistrome and dissect it into functional classes, 
by merging all genomic and epigenomic data available. This procedure, applied to ERα, led to new functional 
information and, applied to Glucocorticoid Receptor (GR), correctly identified experimentally validated binding 
sites16. Our strategy consists in a sequence of integration steps that make it flexible and usable in heterogeneous 
contexts for any TR of interest.
Results
Dissecting transcriptional regulator cistromes by data integration. We designed an integrative 
strategy to analyze heterogeneous genomic datasets, focused on the characterization of three critical aspects of the 
genomic activity of the TR of interest (TRI): (1) definition of binding sites that are robustly reproducible through 
different ChIP studies, i.e. a reference cistrome; (2) the co-factors and co-regulators that co-occupy these genomic 
regions; (3) the epigenetic status of TRI cistrome.
These issues are addressed in separate but converging tasks, as illustrated in Fig. 1a. Results are merged into 
a coherent analytical approach starting with the definition of a consensus reference cistrome for the TRI. The 
successive superimposition of co-factors/co-regulators ChIP genomic signal profiles, chromatin states, and other 
independent genomic features (e.g. transcriptomics), lead to dissection of the cistrome into classes of TRBSs 
with different functional activity. In this procedure, we have applied both novel and public methods for ChIP 
peaks overlapping, normalization and correlation of ChIP genomic signal profiles, and unsupervised prediction 
of redundant patterns of epigenetic modifications (chromatin states).
The first task (blue boxes in Fig. 1a) is designed to define a TRI reference cistrome, reproducibly measured in 
a given experimental setting. We retrieve TRI peak sets from public repositories17, 18 and pre-process them into 
high-level data structures. Then, we integrate the peak sets into a reference cistrome by progressively overlapping 
their genomic coordinates. A novel algorithm called RefGen, which applies a majority vote-based approach to 
identify a reproducible set of TRBSs according to a selected “severity” grade, has been implemented to this pur-
pose (see Materials and Methods).
Cooperative binding of TFs and coregulators is a key feature of genomic regulatory regions. The second task 
(green boxes in Fig. 1a) is designed to identify TRs binding at regulatory regions defined in the first task. This is 
obtained by selecting and downloading appropriate datasets from the same experimental context, then by con-
verting ChIP read alignment files into genomic signal profiles. In this analysis, we consider both the shape and the 
intensity of ChIP signals. Their integration is then carried out in two steps: first, signal profiles are normalized to 
account for the experimental differences among datasets; then, they are joined into a reference genomic profile, 
defined for each TR analyzed. To normalize ChIP data, we implemented a novel algorithm called NormChIP 
which computes a scaling factor to correct each genomic signal profile. Then a correlation between these signals 
and the signal profile of the TRI is computed. The use of normalized signal profiles allows comparing the genomic 
occupancy of multiple TRs at specific genomic regions, or at the whole cistrome level. Factors associated with TRI 
at the highest correlation level are the best candidates as TRI cooperating factors.
The third task (red boxes in Fig. 1a) is focus on the integration of epigenomic data. The epigenome is a piv-
otal regulatory layer for TF and co-regulator binding, since it reflects the accessibility and activity of chromatin 
regions. For the epigenetic classification of TRBSs, we collect reads alignment files of ChIP experiments of histone 
PTMs, histone isoforms, and relevant chromatin-associated proteins from public repositories and pre-process 
data into binarized genomic signals. These data are used as input for the segmentation algorithm Spectacle19 
that integrates data into a discrete number of chromatin states. We use these states to deconstruct the reference 
cistrome following the epigenetic context in which TRI chromatin binding occurred.
Finally, the functional classes of TRBSs identified by this strategy are further improved with information 
derived from independent genomic and gene expression data.
Definition of an ERα reference cistrome. The human breast carcinoma cell line MCF-7 is the most used 
model system for estrogen-dependent breast cancer and was included in ENCODE Tier 21. The number and dis-
tribution of ERα Binding Sites (ERBSs) change drastically in response to hormones in these cells20. The majority 
of studies concern the genomic response to estrogen or the baseline genomic status in cells exposed chronically 
to low-dose estrogen. In addition, we described a dataset of ERα activity in MCF-7 cells in absence of hormones15 
that is comparable to data in other datasets, when cells are “vehicle”-treated, as control.
To test the procedure for reference cistrome definition, we focused at first on the most studied condition, i.e. 
cells cultured continuously in low-dose estrogen (E2-constitutive) and recovered 14 ERα ChIP datasets obtained 
in six independent studies (Supplementary Table 1a). For each study, we identified the ERBSs detected in each 
biological replicate, defining a study-specific cistrome. Then, we merged the cistromes into an E2-constitutive ref-
erence ERα cistrome by selecting the ERBSs identified in at a least 75% of the studies (Fig. 1b) (see Materials and 
Methods for selection criterion). This cistrome is composed of 10,779 highly reproducible ERBSs (Supplementary 
Table 2a), whereas 23,996 were left over (dismissed ERBS). Then, we compared the properties of reference versus 
dismissed ERBSs (Supplementary Table 2b). Reference ERBSs were definitely more enriched in ERα Response 
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Element (ERE), centred in the peak sequences (43.89% vs 24.33% of dismissed) (Fig. 1c,d). Reference ERBSs 
displayed higher overlap with “ERα-bound active enhancer in MCF-7”21 (9,01% vs 0.74%) and with sites of 
long-range chromatin interaction1 (11.43% vs 2.08%). Furthermore, reference ERBSs were enriched in sites 
detected in primary tumors from patients receiving adjuvant Aromatase Inhibitors (AI) or Tamoxifen (TAM) 
(1.08–2.33% vs 0.02–0.07%)22, 23, or metastases (26.86% vs 4.06%)22 (Fig. 1d). Noteworthy, 14 dismissed ERBSs 
overlapped ENCODE blacklisted regions of false positive peak calling. Thus, simply applying a majority voting 
filtering to multiple dataset is sufficient to identify binding sites that are most likely more relevant and less erratic. 
As discussed above, ERα binding to chromatin varies depending on the magnitude and duration of the estrogenic 
stimulus, and evidence exists that these cistromes may have different function, which has not been worked out 
yet. Therefore, we set out to identify context-specific cistromes, together with a wider “consensus” cistrome. We 
subdivided available MCF-7 datasets in three groups defined by the experimental context: (i) transient hormone 
deprivation (E2-Independent); (ii) 45 to 60 minutes E2 treatment (E2-Early); (iii) three to four hours E2 treatment 
(E2-Late); in addition to the E2-Constitutive described above. We integrated a total of 33 datasets derived from 
17 studies, including our own (Supplementary Table 1a, Fig. 2a). By applying the same procedure used above, we 
defined four context-specific cistromes (Supplementary Table 3a–b, Supplementary Figure 1a) which comprised 
quite different numbers of ERBSs (Fig. 2b).
Finally, they were merged into a general ERα cistrome for MCF-7 (ERα-Ref), composed by 13,239 ERBSs. 
These sites present variable degree of co-occurrence in the different experimental contexts. Consequently, we 
Figure 1. An integrative strategy to analyze ChIP data. (a) Schematic representation of our integrative 
strategy applied in the analysis of the cistrome of a Transcriptional Regulator of Interested (TRI). Each column 
represents an analytical step designed to characterize the reference cistrome (left column, blue boxes), the 
TRI candidate cofactors (center column, green boxes), and the epigenetic classes of TRI binding sites (right 
column, red boxes). Rectangles indicate input and output data and the main analytical methods applied are 
reported. TF, Transcription Factor; CoR, Co-Regulator. (b) Box plot representing as blue dots the number of 
ERα Binding Sites (ERBSs) identified in at least a specified number of ERα ChIP studies performed in MCF-7 
grown in estrogens-enriched medium (E2-Constitutive experimental context). Black box plots represent 
the number of random genomic regions with the same length that are overlapped using the same threshold 
(τ) selected for the ERBSs analysis. The red dashed bar indicates the threshold corresponding to the 75% of 
studies that we selected to define the ERα cistrome for the E2-Constitutive experimental context. (c) Line plot 
representing the probability of the Estrogen Response Element (ERE) motif within a window of +/−100 bp 
centered on E2-Constitutive ERBSs belonging to the E2-Constitutive cistrome (Reference ERBSs) or that were 
filtered-out by our analysis (Dismissed ERBSs). At top, the p-value from the motif analysis is reported. (d) 
Fraction of E2-Constitutive ERBSs overlapping independent genomic features including: ERE motif, ENCODE 
blacklisted genomic regions, ERα bound active enhancers previously identified in MCF-7 (Active Enhancer), 
genomic regions of ERα-mediated long-range chromatin interactions (ChIA-PET), genomic regions amplified 
or heterozygous deleted in MCF-7, ERBSs identified in breast cancer tissue from patients before receiving 
Aromatase Inhibitor (AI) or Tamoxifen (Tam) and that responded (R) or not (NR) to treatment, ERBSs 
identified in distal breast cancer metastases, and the list of variants from the iCOGS project.
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subdivided ERα-Ref in four subsets (C1–C4), following the ERBS presence in one, two, three or all the contexts 
(Fig. 2b,c). 50.1% of the ERBSs (6,726) in ERα-Ref were unique to one experimental context (C1), while only 
1,119 ERBSs (8.5%) were common to all the experimental contexts (C4). ERBSs that are detected by ChIP in 
Figure 2. The ERα reference cistrome (ERα-Ref) for MCF-7 cells. (a) Schematic representation of our strategy 
applied in the analysis of the ERα cistrome. (b) Bar plot reporting the ERα-Ref as divided by the experimental 
contexts or as a whole (fifth bar) and divided in co-occurrence subsets, i.e. ERBSs are classified in four subsets 
depending on whether they occur in a single context (C1), in two (C2), in three (C3) or in all the experimental 
contexts (C4) (increasing grey scale). At top of each bar, the number of ERBSs in each cistrome is reported. (c) 
Distribution of each context-specific cistrome (colors) into the C1–C4 subsets, inside each subset, ERBSs are 
ranked simply by their genomic coordinates. Red: E2-Independent; Orange: E2-Early; Green: E2-Late; Blue: E2-
Constitutive; White: no binding detected. (d) Intensity heat map of a time-course ERα ChIP-Seq experiment 
performed in untreated or E2-treated MCF-7. (e) Box plot reporting for each time point, the distribution of average 
ERα ChIP-Seq read counts computed in a window of ±200 bp around ERBSs center. P-value from Mann-Kendall 
test considering the mean and the variance of each distribution. (f) Heat map reporting in blue the ERBSs overlapped 
with independent genomic features including: ERα bound active enhancers previously identified in MCF-7 (Active 
Enhancer), genomic regions of ERα-mediated long-range chromatin interactions (ChIA-PET), ERBSs identified in 
primary tumors from breast cancer patients who responded (R) or not (NR) to adjuvant treatment with Aromatase 
Inhibitor (AI) or Tamoxifen (Tam); ERBSs identified in distal breast cancer metastases; and the list of variants from 
iCOGS project. (g–h) Dot plot reporting, the average Pearson correlation coefficient computed between ERα ChIP 
signal and the signal of different TRs, chromatin accessibility signals measured by DNase-Seq experiment, and ChIP-
Seq against ERα phosphorylation at Serine 118 (S118). The result for each ERα-Ref subset is reported.
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all contexts may represent sites at higher affinity. Therefore, we analysed the differences in the intensity of the 
normalized ERα ChIP peaks, which revealed a progressive increment in the intensity of ERα binding from C1 
to C4 (Supplementary Fig. 1b). Consistently, we measured an enrichment of ERE motifs (ESR1, MA0112.2) in 
C3–C4, explaining increased affinity of these more constantly bound sites (Supplementary Figure 1c). It should 
be noted, however, that these sites are not saturated: considering an independent study on ERα binding at 2, 5, 
10, and 40 minutes after E2 treatment24, we observed a distinct and rapid increment of the ERα ChIP-Seq signal 
in C3 and C4 (Fig. 2d,e).
We next explored possible sequence differences in these co-occurrence groups. Using a +/−100 bp inter-
val around ERBSs, we predicted higher representation of c-Fos (FOS, MA0476.1) and GATA Binding Protein 3 
motifs (GATA3, MA0037.2) in C1–C2 ERBSs (chi-square p-value < 0.05), whereas CREB (CREB1, MA0018.2) 
and Tumor Protein 63 (TP63, MA0525.1) motifs were more enriched in C4 ERBSs (chi-square p-value < 0.001) 
(Supplementary Figure 1d). The motifs of well-known ERα co-factors Forkhead-box protein A1 (FoxA1) and 
Activator Protein 2γ (AP2γ) were enriched but equally distributed among the ERα-Ref subsets. As seen above for 
the E2-Constitutive ERBSs cistrome, we also evaluated the overlap of ERα-Ref with public data from breast can-
cer cell lines and tissues (Supplementary Table 3c). Interestingly, ERBSs previously classified as active enhancers, 
regions involved in long-range chromatin interactions or ERBSs identified by ChIP-Seq in tumor tissues were 
extensively overlapped to C4 and C3 subsets (Fig. 2f and Supplementary Figure 2a).
As far as the context-specific cistromes are concerned, a high fraction of ERBSs observed in E2-Constitutive 
and E2-Late contexts belonged to the C1 subset (40.5% and 28.1%, respectively) while E2-Independent and 
E2-Early were C4 and C3 ERBSs, suggesting that they represent the set with the highest-affinity for ERα.
Then, with our integrative analysis we defined a reference cistrome of ERα chromatin binding in MCF-7 
with a joint analysis of multiple ChIP datasets and we identified the binding sites characterized by persistent 
receptor-chromatin interaction in hormone-deprived and treated cells.
Thus, our integrative strategy was successful in identify subsets of ERα chromatin binding sites in MCF-7 with 
different features.
Cofactors and coregulators overlay. To the goal of featuring factors that cooperate with ERα on chro-
matin, we retrieved the datasets relative to nine TFs and eight co-regulators ChIP in MCF-7 cells, in at least two 
of the four experimental contexts considered for the definition of the ERα-Ref (Supplementary Table 1b). A total 
of 128 ChIP datasets were included in this analysis. DNase-seq datasets were also included. After re-aligning 
the datasets, we computed the genomic signal profiles relative to the ERα-Ref regions, for each TR. These were 
subsequently used to compute a pairwise Pearson correlation with the ERα ChIP signal profile for each ERBS. 
Results showed in Fig. 2g,h for E2-Early and E2-Constitutive and in Supplementary Figure 2b for E2-Late and 
E2-Constitutive, report the average correlation computed in ERα-Ref subsets (C1–C4). Interestingly, we found 
clear differences in cofactor binding in several experimental contexts: E2-Independent ERBSs showed, uniquely, 
at first ranks the Forkhead box protein M1 (FoxM1), the Double-strand-break repair protein rad21 homolog 
(Rad21), which is a component of the cohesin complex involved in enhancer-promoter looping25, and the CBP 
coactivator (Fig. 2g), whereas E2-induced sites presented FoxA1, AP2γ and GATA3 at first places (Fig. 2h), as 
reported by many studies26–28. In this latter subset, a clear correlation with “active” ERα serine 118 phosphoryla-
tion was accompanied by the highest correlation with DNaseI-seq signals demonstrating increased accessibility 
of ERBSs upon E2 stimulation (Fig. 2h). It should be stressed that C4 ERBSs consistently showed the highest level 
of correlation in all the experimental contexts, as expected due to the heterogeneous nature of other subsets.
Epigenetic classification of ERα-Ref. We classified the whole MCF-7 epigenome using 41 ChIP datasets 
relative to six histone modifications and five regulatory proteins (Supplementary Table 1b). We predicted 15 chro-
matin states in three experimental contexts (Fig. 3a and Supplementary Figure 2c, Supplementary Table 4a–b). 
The number of datasets in the E2-late context was not sufficient to generate this classification. Focusing on the 
chromatin states typical of Enhancers (Enh-), Promoters (Tss-) and intragenic regions (Gene-), we observed that 
the different experimental contexts were characterized by specific combinations of chromatin features (Fig. 3a 
and Supplementary Figure 2c). In fact, the epigenome of cells exposed to estrogen (E2-Early, E2-Constitutive) 
was characterized by five states related to gene transcription/intragenic regions and three enhancer states, while 
in E2-Independent an additional enhancer state, featured by RNA Polymerase II (RNAPII), H3K27ac, and 
H3K4me1, was uniquely predicted, which we named Enhancer-Transcribed (EnhT) (Fig. 3a). Then, we super-
imposed the chromatin states to the ERα-Ref, observing as expected a general enrichment of ERBSs in enhancer 
classes, (Fig. 3b and Supplementary Figure 2d). Noteworthy, ERBSs subsets defined either by the different exper-
imental contexts or by co-occurrence (C1–C4) were neatly discriminated, as shown in Fig. 3b (further detailed 
below).
In addition to RNAPII binding, bi-directional transcription of eRNAs is taken as a marker of enhancer activ-
ity. Therefore, we took advantage of a time-course analysis after E2-treatment, by nuclear run-on followed by NGS 
(GRO-Seq)29–31. We observed that only a fraction of ERBSs shows robust induction of eRNAs transcription, and 
C4–C3 ERBSs were the subsets in which most of the sites presented induction of eRNAs in response to estrogen 
(Supplementary Figure 3a–b).
The different features of context-dependent ERBSs were especially intriguing. Indeed, E2-independent were 
predominantly classified as EnhT and Active Enhancer (EnhA), whereas other contexts were mostly classi-
fied as EnhA and TssA (Fig. 3b and Supplementary Figure 2d). Figure 3c shows that features of EnhT class in 
E2-Independent ERBSs are high H3K27ac and RNAPII levels. This suggests transcription at these sites. Thus, 
we isolated the fraction of ERα-Ref occupied by ERα in the E2-Independent context, which are mostly classified 
as enhancers (78.5%), specifically, EnhA (30.5%), EnhT (22.7%), and Enhancer-Weak (EnhW, 18.9%) (Fig. 3c 
and Supplementary Table 5a). Unexpectedly, by examining the cited experiment of GRO-seq29–31, we observed 
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bidirectional eRNAs transcription around EnhT ERBSs, even at point 0, i.e. before estrogen stimulation (Fig. 3c). 
Four independent public GRO-Seq experiments performed in hormone-deprived cells confirmed this find-
ing (Supplementary Figure 3c). Thus, overlaying context-specific cistromes with epigenetic data allowed us to 
discover an unexpected feature of sites occupied by unliganded ERα, that is eRNAs transcription, marker of 
enhancer activity.
Then, our strategy can be applied to narrow down a list of TR binding sites to a subset of interaction that are 
predicted to be functionally relevant for their cistromic, epigenomic and TR interactions properties.
The glucocorticoid receptor cistrome of A549 cells. We evaluated the performance of our strategy on a 
second independent case-study concerning the Glucocorticoid Receptor (GR) cistrome in lung cancer A549 cells. 
Recently, a GR-ChIP-seq library was experimentally validated in reporter assays in response to Dexamethasone 
(DEX) treatment16. Thus, experimental classification of GRBSs will provide ideal challenge for our integrative 
procedure. Following our strategy, we first integrated four GR ChIP datasets from cells treated with DEX for 1 
(DEX-Early) or 3 hours (DEX-Late) (Fig. 4a, Supplementary Table 1a), defining a GR cistrome (GR-Ref) com-
posed of 13,466 GRBSs. 5,491 (40.03%) of these were occupied by GR in both the experimental contexts (C2) 
Figure 3. Epigenetic-based classification of the ERα-Ref. (a) Heat maps reporting the frequency of significant 
ChIP signal of epigenetic modifications, TFs, and co-regulators overlapping the MCF-7 chromatin states 
predicted for the E2-Independent (top) and E2-Early (bottom) experimental contexts. (b) Heat map reporting 
the enrichment of the overlap between chromatin states and genomic annotations for the two experimental 
contexts considered. These annotations include: coordinates of regions involved in long-range chromatin 
interactions (ChIA-PET), ERBSs identified in tumors from breast cancer patients before receiving Aromatase 
Inhibitor (AI) or Tamoxifen (Tam) and that responded (R) or not (NR) to treatment, and list of variants from 
iCOGS project. (c) Intensity heat map reporting the normalized signal of different ChIP-Seq experiments 
measured in a window of ±5 kbp centered on each E2-Independent ERBS. The signal of ERα and H3K27ac, 
H3K4me1 and H3K4me3 histone modifications is reported on the left. The signal of the three ERα-correlated 
TFs and co-regulators is reported in the center. The signal of a RNAPII ChIP-Seq and a GRO-Seq experiment of 
E2-treated MCF-7 is reported on the right.
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(Fig. 4b,c and Supplementary Table 6a–b). Most GRBSs were present only in one experimental context (C1) 
and were prevalently identified in the DEX-Late context (69.67%). Then, GR-Ref was compared to the validated 
GRBSs, observing that 95.6% of validated GRBSs overlapped GR-Ref. Importantly, 19.4% of C2 GRBS overlapped 
validated GRBSs as compared to only 3,2% of C1 GRBSs (Fig. 4d).
For the second step of our strategy, we collected 26 ChIP datasets relative to four TRs from ENCODE experi-
ments in A549 cells treated with vehicle (DEX-Independent) or DEX for 1 hour (DEX-Early). After normalization, 
we calculated the correlations with GR genomic signals, and we observed a clear increase of the average correla-
tion coefficient from DEX-Independent to DEX-Early context (Fig. 4e,f). Specifically, cAMP Responsive Element 
Binding protein 1 (CREB1), FoxA1 and Upstream Stimulatory Factor 1 (USF1) were highly correlated (r > 0.6) 
with GR binding signal in DEX-treated cells, while less correlation with CTCF and RNAPII was observed. 
Interestingly, the rank of GRBSs based on the average correlation computed for these three TFs revealed that the 
Figure 4. Integrative analysis of GR cistrome in A549 cell lines. (a) Schematic representation of our strategy 
applied in the analysis of the GR cistrome in A549 cells. (b) Bar plot reporting the GR-Ref as divided by the 
experimental contexts or as a whole (third bar) and divided in co-occurrence subsets, i.e. GRBSs are classified 
in two subsets depending on whether they occur in a single context (C1), or in the two experimental contexts 
considered (C2) (increasing grey scale). At top of each bar, the number of GRBSs in each cistrome is reported. 
(c) Representation of the distribution of GRBSs belonging to the two subsets in each context-specific cistrome 
is reported. GRBSs are organized by co-occurrence in different experimental contexts and then ranked by 
genomic coordinates. (d) Heat map reporting in blue the GRBSs overlapping experimentally validated DEX-
Responsive GRBSs. (e) Intensity heat map of GR ChIP-Seq experiment performed in untreated or DEX-treated 
A549 cells. (f) Dot plot reporting, the average Pearson correlation coefficient computed between GR ChIP-Seq 
signal and the signal of different TRs. The result for each GR-Ref subset is reported. (g) Fraction of GR-Ref 
subsets classified in a specific chromatin state using the Spectacle algorithm19.
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top quartiles of GRBSs was also associated with the highest superimposition with the validated GRBS set (24.34% 
of overlapped sites) (Supplementary Table 6c). As a third step, we predicted 15 chromatin states in A549 cells 
(Supplementary Table 6d and Supplementary Figure 3d), by integrating 32 ChIP datasets relative to eight epige-
netic modifications (Supplementary Tables 1b). In DEX-Early, most C2–C1 GRBSs demonstrated a chromatin 
state (Enh-TssA) shared by both enhancers and promoters (H3K4me3, H3K4me1, and H3K27ac), while only C1 
were enriched in gene body marks (H3K79me2 and H3K36me3) (Fig. 4g, Supplementary Figure 3e). Considering 
the three more represented classes of GRBSs (Enh-TssA, Enh-Tss-Gene-5′, and EnhW) we observed that vali-
dated GRBSs in the C2 subset were mostly classified as Enh-TssA and to a lesser extent as Enh-Tss-Gene-5’ and 
EnhW (Fig. 4h).
Thus, classification of GR binding through cistrome integration, cofactor analysis and epigenetic features 
allows identification of functionally relevant sites.
Discussion
In this work, we present a strategy to guide the reuse, combination, and post-processing analysis of NGS data 
describing regulatory protein-chromatin interaction. Analysis of one case-study of ERα in MCF-7 cells, where 
extraordinarily rich data exist, and GR in A549 cells, where experimentally validated binding sites were pub-
lished, confirmed the validity of this strategy. In the first case, feasibility with abundant data, i.e. computationally 
demanding, was verified. In the second case, the paucity of data did not hamper adherence of results to exper-
imental validation. It should be stressed that, in the first case, this analysis provided valuable new information 
on the less studied experimental context - absence of hormones - which is of great interest since hormone depri-
vation is the therapeutic strategy of drugs as Aromatase Inhibitors in Breast Cancer32. The novelty is assembling 
all available TFBS, epigenomic and transcriptomic data in a coherent strategy to functionally classify chromatin 
binding events of any transcriptional regulator. Two novel methods were developed and implemented to define 
consensus cistromes and to normalize ChIP genomic signal profiles. Moreover, a full integration approach is 
proposed in association with chromatin states prediction algorithms.
The variability of ChIP measurements is due to many factors, starting from the antibody used to the assay pro-
tocol and NGS platform33. For cistrome definition we used an algorithm based on the majority voting approach, 
which allows extrapolating the consensus coordinates of TRI binding. This is a computationally efficient strategy 
to overlap multiple datasets34 that does not require a threshold based on the minimal number of overlapped 
nucleotides or peak centre position, allowing the analysis of NGS datasets in heterogeneous formats. Moreover, 
this procedure prompts easy and quick update whenever new data is available. In the case of ERα, the efficiency 
was evaluated by measuring consistency with functionally relevant datasets (e.g. tumors data). For GR, overlap 
with peaks reportedly active in luciferase reporter assay16 measured the performance of our analysis.
Regulatory regions are sites of binding of multiple DNA-binding or coregulatory proteins. Describing 
co-occupation profiles is commonly performed by superposition of genomic intervals1, 8, without considering the 
signal profiles obtained from NGS experiments. Here we propose to combine normalization and correlation anal-
ysis of different signal profiles. We adapted the normalization method implemented in DESeq library35 on a set 
of NGS experiments, because this method was previously observed to be effective in differential binding analysis 
on the normalized number of ChIP reads mapping to regulatory regions22. Correlation between the normalized 
signal profiles of TRI and other TRs gives a measure of co-occupancy. The analysis is optimized to compare uni-
modal genomic signal profiles in the region of chromatin interaction. We are currently working on the extension 
of our method to multimodal spread signals characterizing some TR complexes. Finally, we propose the classifi-
cation of TRBSs into functional classes based on redundant patterns of cistromic and epigenomic ChIP signals. 
Our strategy is to classify the epigenome of the experimental model system into a discrete number of chromatin 
states, subsequently superimposed to the TRI cistrome, whereas other integrative tools like Seqminer9 or EaSeq.10 
exploit the simple co-occurrence of ChIP-derived patterns, more prone to some bias. In conclusion, our strategy 
merges new and public algorithms into a coherent process leading to cistrome definition and classification, using 
extensive integration of genomic and epigenomic data, in the cell/tissue model system considered. Computational 
tools like EaSeq.10, HiChIP36, Cistrome37, or CisGenome38 assembly validated algorithms to perform restricted 
single-step analysis.
Considering ERα analysis, although it was hard to imagine adding value to such an extensively studied field15, 39, 40, 
our strategy revealed at least two undescribed features: first, our novel classification in co-occurrence subsets (C1–
C4) revealed that ERBSs common to all contexts (C4), i.e. in both presence and absence of hormones, are a pecu-
liar subset, showing the strongest ChIP signal and the most significant co-occupancy by co-factors; they represent 
undoubtedly lineage-specific, highly accessible chromatin sites for ERα, and in fact they appear the only ones to 
quickly respond to E2 stimulation by eRNAs transcription. The second unexpected observation was that ERBSs 
in absence of hormones15 display features of active enhancers (EnhT) considering both histone PTMs and eRNAs 
transcription. Furthermore, transcription factor FoxM1, Steroid Receptor Coactivator 1 (SRC1) and the cohesin 
complex component Rad21 were quite specific to this set. While hormone-independent occupancy of ERBSs 
by FoxA1, AP2γ and Rad21 at ERBSs was previously demonstrated15, 26, 28, 41, our data show FoxM1 as the most 
correlated protein in hormone-deprived cells. FoxM1 is an important factor for breast cancer cell growth42, 43. 
Importantly, FoxM1 and ERα regulate the expression of each other44, 45.
One criticism to our ERα analysis is that the final characterization of differential functions for ERBSs is 
deducted based on the same kind of data by which it was classified, i.e. indirect data linked to epigenetic features 
and eRNAs transcription, but lacks stronger experimental proofs, such as target gene regulation. However, ERBSs 
are generally distant from TSS of regulated genes and rationale matching is not trivial: we are currently working 
to integrate HiC looping data in our pipeline. We ran preliminary analysis based on proximity using previously 
published RNA-seq15. GREAT analysis46 showed that EnhT ERBSs-proximal genes are neatly linked to “gland 
development” and “gland morphogenesis” (Supplementary Figure 4a and Supplementary Table 5b) suggested as 
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a specific function of ERα15, whereas other Enh- classes showed more dispersed terms. Consistently, Gene Set 
Enrichment Analysis (GSEA) demonstrated EnhT ERBSs enrichment in several datasets related to breast cancer 
and estrogen response (Supplementary Table 5c). It is worth noticing that EnhT ERBSs were also significantly 
closer to the TSS of genes previously reported to be regulated by ERα in the E2-Independent context, especially for 
genes that are down-regulated following ERα ablation15 (Supplementary Figure 4b). Similarly, EnhT ERBSs were 
associated with the highest number of genes that change upon ERα silencing within 100 kbp (134 genes, 14.3%) 
(Supplementary Figure 4c and Supplementary Table 5d). E2-Independent EnhT ERBSs were found relatively near 
or intronic to several genes encoding for TFs important for mammary gland development, i.e. SPDEF, TFAP2C, 
MYB, RARA, ELF3, and the ESR1 gene itself (Supplementary Table 5e), known ERα target genes (FOS, XBP1, 
TFF1, EGR3) and several long noncoding RNA genes, including DSCAM-AS1, an ERα-dependent lncRNA spe-
cific to luminal breast tumors47. The analysis of GRBSs was also informative. In all the steps of our procedure we 
observed enrichment of experimentally validated GRBSs in specific subsets selected in the different steps of our 
procedure. Again, it would be desirable to obtain direct proofs of gene regulation. Although GRBSs are more 
frequently proximal to TSS48, association to regulated genes is questionable. Indicatively, one RNA-Seq experi-
ment of DEX-treated A549 pointed to 644 responsive genes, three-fourth of them within 100 kbp from a GRBSs 
belonging to GR-Ref (Supplementary Table 6e–f). Most of these GRBSs co-occurred in the experimental contexts 
and 42.5% were classified as Enh-TssA (Supplementary Figure 4d). Despite the limited number of datasets inte-
grated in this case, the classification reached is sound with the function.
In conclusion, results obtained in these case-studies suggest that our strategy can be applied to any TR of 
interest to extract novel information to be tested in experimental settings.
Methods
Datasets. To define the ERα reference cistrome for the MCF-7 cells (ERα-Ref), 33 sets of ERBSs were 
retrieved from GEO18, Array Express17, Cistrome37, and supplementary material of target publications. To define 
the GR reference cistrome for A549 cells four sets of GRBSs were retrieved from GEO. All the analysed datasets 
are reported in Supplementary Table 1a. To make the genomic coordinates of all datasets comparable, they were 
converted to hg19/GRCh37 human genome assembly using the LiftOver algorithm49. Moreover, ERBSs mapped 
on chromosome Y were removed.
Data of ChIP experiment against TFs, co-regulators, histone modifications and ERα Serine 188 phosphoryl-
ation were collected from Array Express and GEO. Datasets of DNaseI-Seq assays were retrieved from GEO. The 
data of a time-course experiment of ERα ChIP-Seq were downloaded from GSE5485524. All the datasets used in 
the analysis are reported in Supplementary Table 1b.
Reference cistrome definition. The definition of a TR reference cistrome was performed by taking as 
input a list of genomic intervals corresponding to the TRBSs obtained in a set of ChIP experiments. Then, the 
reference cistrome is composed by the genomic positions which are shared by a desired number of experiments 
(τ). To efficiently define this reference, an ad-hoc algorithm, namely RefGen, is proposed. In details RefGen first 
exploits the lists of genomic intervals to generate a genomic coverage (i.e. the intervals overlapping values for each 
genomic position), then the genomic position characterized by a coverage value greater than or equal to a prede-
fined threshold τ are selected as reference cistrome. The pseudo-code of RefGen is reported in the Supplementary 
Note section, and its C++ implementation is available at: https://github.com/giuferrero/RefGen.
This program is free software; you can redistribute it and/or modify it under the terms of the GNU General 
Public License as published by the Free Software Foundation; either version 2 of the License, or (at your option) 
any later version.
Definition of the ERα and the GR cistromes. In the ERα case study RefGen was first applied to gen-
erate a reference cistrome from the biological replicates of 17 independent ChIP experiments (Supplementary 
Table 1a). In this step, for each experiment, the binding sites identified in all biological replicates were selected. 
Then, the resulting cistromes (i.e. one for each experiment) were divided into four subsets based on the exper-
imental context in which they were performed: (i) transient hormone deprivation (E2-Independent); (ii) 45 to 
60 minutes E2 treatment (E2-Early); (iii) three to four hours E2 treatment (E2-Late); and (iv) continuous cell 
growth in estrogen-enriched medium (E2-Constitutive).
For each of the four experimental contexts, the cistromes of the experiments belonging to the same experi-
mental context were further processed by RefGen to generate a specific experimental context cistrome. A τ value 
equal to 75% of the number of input cistromes was applied on these runs. The τ threshold used in these analyses 
are reported in Supplementary Table 3a. This threshold was selected after comparison of the number of genomic 
regions obtained using random datasets (Fig. 1b and Supplementary Figure 1a). Specifically, 1,000 random ref-
erence cistromes were defined for each experimental context by considering the same number of input genomic 
intervals with the same length. These random genomic intervals were generated using the shuffleBed function of 
bedtools50 with option -chrmon. The threshold was selected to better balance the rate of false positive/false nega-
tive predictions. A main reference cistrome (ERα-Ref) was also derived by the application of RefGen on the four 
context-specific cistromes. For this analysis, the binding sites identified at least in one experimental context were 
selected. The same procedure was applied to define the GR cistrome for each of the two analysed experimental 
contexts (DEX-Early, DEX-Late).
Cistromes overlap with independent genomic features from public datasets. The overlap 
between ERBSs and ERα GIS-ChIA-PET data from the ENCODE project was performed using the coordinates of 
ChIA-PET anchor regions retrieved from GSM97021217. An overlap was confirmed valid if observed for two out 
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of three available ChIA-PET biological replicates. The overlap between ERBSs and a list of 1,248 ERα/H3K27ac 
co-bound enhancers (Active Enhancers) was performed using the list provided in ref. 21.
ChIP-Seq on primary tumor biopsies from breast cancer patients taken at surgery before treatment with 
Aromatase Inhibitor (AI) or Tamoxifen (TAM) were downloaded from GSE4086711 and GSE3222246 respec-
tively. Data of patients responsive or not to therapy were considered separately to define an ERα cistrome for 
each treatment outcome. Three sets of ERBSs defined in metastatic breast cancer samples were also considered. 
The cistromes were defined using RefGen by setting the τ threshold equal to the number of biological replicates 
available for each patient group.
Coordinates of amplified and heterozygous deleted regions in the MCF-7 were retrieved from GSE406982. 
The overlaps between ERBSs and these regions were considered valid if they were observed in all the available 
biological replicates.
The overlap between the GR cistrome and the set of DEX-Responsive GRBSs was performed by considering 
the set of 1,376 significant bindings sites provided in ref. 16.
Ontological analysis. GREAT algorithm v3.046 was exploited to perform the ontological analysis of the 
genes mapped nearby to ERBSs. Using the default settings of the program, the median distance between ERBSs 
and associated genes was 93,203 bp. The Gene Ontology Biological Process, Cellular Component and Molecular 
Function terms significantly enriched for both the binomial and the hyper-geometric by a p-value lower than 0.05 
were considered.
TF binding motif analysis. Prediction of TF binding motifs was performed using the Centrimo algorithm 
of the MEME-ChIP pipeline v.4.9.151 in default settings. A genomic region of +/−100 bp focused on each binding 
sites center was considered for this analysis.
ChIP signal profiles normalization. The normalization of ChIP signal profiles was performed with a new 
algorithm called NormChIP. This algorithm extends the DESeq normalization method35 on ChIP signal profiles.
The algorithm initially encodes the ChIP signal profiles on a matrix M so that a cell M[j, i] stores the count of 
aligned reads in the j interval/bin of experiment i. For each row M[j, ∗], the NormChIP algorithm computes the 
geometric mean across the counts of bin j in all the experiments as reported in equation (1):
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where N is the total number of experiments.
Then, each row M[j, ∗] is divided by the corresponding GMj,∗ value obtaining a new matrix M0. From the 
matrixM0 a vector s, called size factor, is computed as reported in equation (2):
′ ∗=med M i[ , ] (2)i
N
1
where the med operator returns the median value.
Finally, the normalized ChIP signal profiles are obtained by dividing each column j of the initial matrix M 
with the corresponding size factor s[j].
The pseudo-code of NormChIP is reported in the Supplementary Note section and its C++ implementation 
is available at: https://github.com/giuferrero/NormChIP.
This program is free software; you can redistribute it and/or modify it under the terms of the GNU General 
Public License as published by the Free Software Foundation; either version 2 of the License, or (at your option) 
any later version.
NormChIP was applied to define a reference genomic signal profile for the ERα ChIP experiments. One refer-
ence was generated for each considered experimental context. The raw NGS data of the experiments selected for 
the definition of ERα-Ref were realigned using Bowtie v2.1.052 in default settings. The ERα ChIP signal profiles 
were computed considering a genomic window of ± 5 kbp centered on each ERBS of the ERα-Ref. These regions 
were fractioned in consecutive non-overlapping 50-bp bins and reads aligned within each bin were counted with 
Seqminer53 v1.3.3e in default settings. The genomic signal profiles were normalized using NormChIP. Then, a 
reference for each experimental context was defined by averaging the normalized signal profiles. The same proce-
dure was applied on the GR ChIP-Seq experiments.
NormChIP performance was tested using five ERα ChIP signal profiles obtained by different groups in 
the same experimental condition (E2-Late). The datasets were selected based on the alignment rate (>90%). 
NormChIP normalization was compared to i) the raw signal profile and ii) the signal normalized on the number 
of sequenced reads (count per millions, CPM). Results of the performance test are shown in Supplementary 
Figure 5.
Correlation analysis between ChIP genomic signal profiles. TFs and co-regulators ChIP datasets 
were aligned with Bowtie v2.1.052 in default settings. The available datasets against the same factor and performed 
in the same experimental context were considered in the further analysis if their percentages of aligned reads were 
greater than 80%.
For each factor, the genomic signal profile was normalized using NormChIP. The normalized signal pro-
files obtained in the same experimental contexts were averaged. The resulting signal profiles were also nor-
malized with NormChIP, with respect to different factors measured in the same experimental context. This 
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two-steps normalization strategy was selected to allow both inter-context comparisons (for the same factor) and 
intra-context comparisons (between different factors).
A pair-wise correlation between the signal profile of ERα (or GR) and each of TF/co-regulator signal was 
computed using the Pearson method. The correlation coefficient was computed between signal profiles measured 
in each ERBS (or GRBS). Only ChIP datasets obtained in the same experimental context were compared.
Chromatin states prediction. The chromatin state prediction is performed using the Spectacle algo-
rithm19. Raw reads were aligned using Bowtie v2.1.052 in default settings. The ChIP read alignments of the histone 
modifications, were binarized with the BinarizedBed function of Spectacle. The hg19 genome was fractioned 
in 200 bp non-overlapping bins. Prediction of a 15 chromatin states model, the genome segmentation and the 
features overlap were performed using LearnModel function with options -i = spectral, -lambda = 1 and -comb.
For the ERα case study, the MCF-7 chromatin states were predicted considering ChIP datasets against six 
histone marks, histone acetyltransferase p300, RNAPII, Mediator Complex subunit 1 (MED1), and CTCF. The 
analysis was performed separately to predict the states for E2-Independent, E2-Early and E2-Constitutive exper-
imental contexts. For E2-Early context analysis, the data of H3K9me3 and H3K27me3 of three hours E2-treated 
MCF-7 were considered, since only these datasets were available at the time of the analysis. For the GR case study, 
the A549 chromatin states, eight histone marks and CTCF and RNAPII ChIP experiments were used to predict 
15 chromatin states for the DEX-Early and DEX-Independent experimental context. Details on the criteria cho-
sen to name the chromatin states defined by Spectacle are reported in the Supplementary Note section and in 
Supplementary Table 4.
The fraction of epigenomes associated with each chromatin state were overlapped with independent lists of 
genomic features including: coordinates of Gencode v19 gene body, TSS, Transcription End Sites (TES), CpG 
islands, Lamin B1 associated domains, and amplified or heterozygous deleted genomic regions. The overlap 
against the coordinates of different ERα-Ref (or GR-Ref) subsets was also performed. The overlap with these 
genomic features was computed as previously reported54. Then, enrichments were Z-score converted in order to 
identify the features enriched or depleted in each of the chromatin state.
Gene expression data analysis. Raw gene expression data were retrieved from public repositories without 
further reads quality control. Analysis of GRO-Seq datasets was performed using Bowtie v2.1.0 in default settings 
and the –local option. Three different experiments were considered: GSE4582229, GSE4132431 and GSE2746330. 
The signal profiles of these experiments were computed within a genomic region of ±5 kbp centered on each 
ERBS of the ERα-Ref. RNA-Seq data of hormone-deprived MCF-7 cells transfected with control or ERα-specific 
siRNA from GSE5353215 were analyzed as previously reported47, and by considering Gencode v19 gene annota-
tions and human genome assembly hg19.
Processed data of a RNA-Seq experiment of DEX- or Veh-treated A549 cells were retrieved from GSE79432. 
Differential expression analysis was performed on each gene isoforms using the DESeq. 2 R package35. A tran-
script was considered differently expressed if associated with an adjusted p-value < 0.05.
Gene-set enrichment analysis. The list of EnhT, EnhA and EnhW E2-Independent ERBSs associated with 
the differently expressed genes was defined by considering the E2-Independent ERBSs mapped within 100 kbp 
from the differently expressed genes TSS. The GSEA algorithm55 was used to characterize functionally the genes 
associated with these classes of E2-Independent ERBSs. The preRanked mode of GSEA was applied using 10,000 
random permutations and selecting only the gene-sets associated with a p-value < 0.05. The genes were ranked by 
decreasing number of associated E2-Independent ERBSs and in case of equal number of sites, the absolute log2FC 
of expression in siERα-treated cells was considered. The MSigDB v4.0 gene set library was used for the analysis.
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